Genetic markers of enhanced functional antibody responses to COVID-19 vaccination., PMID:40527060
Hydrophilic Interaction Chromatography HRMS with Acrylamide Monolithic Columns: A Novel Approach for Intact Antibody Glycoform Characterization., PMID:40518936
Native structure of the monoclonal therapeutic CD20 antibody ocrelizumab., PMID:40513927
Patrolling monocytes mediate virus neutralizing IgG effector functions: beyond neutralization capacity., PMID:40510351
Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation., PMID:40506471
FcRn inhibitors in immune thrombocytopenia: A comprehensive review of therapeutic advances and clinical outcomes., PMID:40505332
An Unusual Presentation of Bullous Skin Lesions During Pregnancy., PMID:40503690
IgG2b enhances alloantibodies to stored red blood cells., PMID:40485608
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodies., PMID:40464120
Human Fcγ-receptors selectively respond to C-reactive protein isoforms., PMID:40458392
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603
Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study., PMID:40437463
Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein., PMID:40436929
Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2., PMID:40431678
Balancing Reactivity and Specificity: Fc-Binding O-Acyl Hydroxamate Reagents for Site-Selective Antibody Labeling at Lys248., PMID:40423997
Fate of Stressed Oligoclonal Antibodies Tracked by Fluorescence Cross-Correlation Spectroscopy: IgG Aggregation Proceeds across the Species Barrier., PMID:40408563
Real world study in Italian public hospital with Efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors., PMID:40401017
Antibody Labeling With FITC Facilitates Controlled Release From Peptide Hydrogels Bearing Fc-Binding Motifs., PMID:40400208
Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis., PMID:40395177
Chronic Inflammatory Demyelinating Polyneuropathy: How Pathophysiology Can Guide Treatment., PMID:40391517
Pharmacokinetics, Pharmacodynamics, and Safety of Nipocalimab in Healthy Chinese Volunteers: A Single-Dose, Phase I Study., PMID:40389701
Molecular determinants of sialylated IgG anti-inflammatory activity., PMID:40377989
Engineering of long-acting human growth hormone-Fc fusion proteins: Effects of valency, fusion position, and linker design on pharmacokinetics and efficacy., PMID:40373007
Virtual Screening Combined with Phase Transition-FRET for Discovery of Small-Molecule FcRn Antagonists., PMID:40369714
Identifying Neurological Autoantibodies in COVID-19: mGluR2 as a Marker of Immune Dysregulation During the Omicron Outbreak in China., PMID:40343769
A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits humoral immunity similar to that of postfusion gB in mice., PMID:40338082
Leveraging neonatal Fc receptor (FcRn) to enhance antibody transport across the blood brain barrier., PMID:40319060
Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis., PMID:40313945
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab., PMID:40311014
Perivascular Niche-Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment., PMID:40300097
Antibody Purification Using Spy Chemistry., PMID:40291418
Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects., PMID:40277145
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity., PMID:40274283
Comprehensive Characterization of IgG2 Disulfide Isoforms Using Native Cation Exchange Chromatography-Mass Spectrometry and Peptide Mapping., PMID:40273039
Impact of Monoclonal Antibody Aggregates on Effector Function Characterization., PMID:40265412
The contemporary management of haemolytic disease of the fetus and newborn., PMID:40263127
Spatial and Sequential Topological Analysis of Molecular Dynamics Simulations of IgG1 Fc Domains., PMID:40261915
Mapping affinity and allostery in human IgG antibody Fc region-Fc γ receptor interactions., PMID:40236212
A randomized, open-label study on the effect of nipocalimab on vaccine responses in healthy participants., PMID:40232701
A novel IgG-Fc-Fused multiepitope vaccine against Brucella: robust immunogenicity., PMID:40229797
An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment., PMID:40207734
Serum Disease-Specific IgG Fc Glycosylation as Potential Biomarkers for Nonproliferative and Proliferative Diabetic Retinopathy Using Mass Spectrometry., PMID:40204274
Neonatal Fc receptor participates in endocytosis of Fc fusion protein in vivo and in vitro., PMID:40187220
Considerations and approaches for early onset fetal anemia due to red cell alloimmunization., PMID:40179608
Innovative use of gram-positive enhancer matrix particles and affinity peptides in a vaccine against Coxsackievirus B3., PMID:40174632
Deciphering HIV vaccine-induced antibody response according to ethnicity., PMID:40162984
Variable domain glycosylation as a marker and modulator of immune responses: Insights into autoimmunity and B-cell malignancies., PMID:40158366
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress., PMID:40156757
HEXA-FC protein therapy increases skeletal muscle glucose uptake and improves glycaemic control in mice with insulin resistance and in a mouse model of type 2 diabetes., PMID:40156616
Enhancing activity of FcαRI-bispecific antibodies using glycoengineering., PMID:40156381
For research use only. Not for human or drug use.
